Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Halts Development Of Diabetes Agent TAK-379

This article was originally published in PharmAsia News

Executive Summary

Takeda announced April 21 it would discontinue clinical development of diabetes agent TAK-379 because it did not meet internal criteria to support further development. An insulin sensitizer, TAK-379 was in Phase II trials in the U.S. and Europe and in Phase I in Japan
Advertisement

Related Content

Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts
Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts
Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion
Takeda Starts Japanese Fiscal Year With Global Reorganization
More data needed for Takeda’s alogliptin
Advertisement
UsernamePublicRestriction

Register

SC071431

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel